Business Wire

Biocytogen’s Subsidiary Eucure Biopharma and Chipscreen Biosciences’ Holding Subsidiary Chipscreen NewWay Biosciences Enter into Greater China License Agreement for Bispecific Antibody YH008


Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced that its wholly owned subsidiary, Eucure (Beijing) Biopharma Co., Ltd. (“Eucure Biopharma”), has reached an exclusive licensing agreement with Chipscreen NewWay Biosciences (“Chipscreen NewWay”), a holding subsidiary of Shenzhen Chipscreen Biosciences Co., Ltd. (“Chipscreen Biosciences”, SSE: 688321) for the clinical development and commercialization of bispecific antibody YH008 in Greater China (including Mainland China, Hong Kong, Macau and Taiwan). Eucure Biopharma retains YH008’s global rights to develop and commercialize YH008 outside Greater China. Under the agreement, Chipscreen NewWay will pay Eucure Biopharma an upfront payment of 40 million RMB, a potential development milestone payment of up to 360 million RMB, a potential sales milestone payment of up to 196 million RMB, as well as tiered royalties on net sales.

YH008 is Biocytogen’s independently developed proprietary bispecific antibody for tumor immunotherapy. The IND application for a phase I study of YH008 was cleared by the US FDA and accepted by the Chinese NMPA.

“Chipscreen Biosciences and Chipscreen NewWay have extensive experience in clinical drug development and commercialization,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “With this agreement in place, we will work together to accelerate YH008’s entry into the market to benefit patients.”

“Biocytogen’s YH008 has unique mechanisms and outstanding preclinical results,” said Dr. Xianping Lu, CEO and President of Chipscreen Biosciences. “This licensing agreement will expand Chipscreen NewWay’s pipeline in the field of antibody drugs and immuno-oncology. I look forward to these fruitful collaborations.”

“The unique mechanism of action of YH008 bring together the synergies of immune activation and immunosuppressive blockade, and can reduce toxic side effects and increase safety,” said Dr. Bin Liu, Head of the Center of Antibody Early R&D at Chipscreen NewWay. “The clinical potential of YH008 is worth looking forward to and it is a good addition to the products under development of Chipscreen NewWay. Chipscreen NewWay will rapidly advance the clinical stage research and development of YH008.”

About YH008

YH008 is a bispecific antibody that exerts antagonistic and agonistic activities. In vitro and in vivo studies indicate that YH008 can conditionally activate the immune pathway in the tumor microenvironment where certain tumor specific T cells are enriched to avoid systemic non-specific activation. Additionally, YH008 was engineered with an Fc-silent IgG1 isotype to avoid Fc-receptor-mediated non-specific immune activation. YH008 demonstrated superior anti-tumor activity when compared to parental monoclonal antibodies (mAbs) or combination therapy in syngeneic models. In vivo pharmacodynamic studies indicate that YH008 can activate tumor-infiltrating DCs and T cells. In addition, both in vivo studies and GLP toxicology studies indicate improved safety of YH008 compared with benchmark mAbs.

About Eucure Biopharma

As a wholly owned subsidiary of Biocytogen, Eucure Biopharma undertakes the mission of clinical development for Biocytogen’s R&D pipelines. Relying on a strong clinical development team and extensive clinical development experience, Eucure Biopharma focuses on antibody drug therapy for oncology and other indications. The company has established a product pipeline for more than 10 targets, with two products in launched phase II multi-regional clinical trials (MRCT) and two in phase I. For details, please visit

About Biocytogen

Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM/RenLite®/RenNano® mice platforms for fully human monoclonal, bispecific/multispecific antibody and nanobody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum. As of June 30, 2022, this project has resulted in 28 drug co-development agreements and 16 RenMiceTM licensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit

About Chipscreen

In 2001, Chipscreen Biosciences was founded in Shenzhen, specializing in the research and development of original small molecule drugs. With the self-created "integrated drug discovery and early evaluation platform based on chemical genetics" as its core competitiveness, Chipscreen Biosciences has now become one of China's leading innovative drug enterprises, forming a modern biomedicine group company in Shenzhen, as its headquarters / research and development center / GMP production base, Chengdu, as a regional headquarter / research and development center / GMP production base, Beijing clinical research center and Shanghai commercial center. At present, the company has developed a number of original new drug product lines for tumors, diabetes, and endocrine and autoimmune diseases. In December 2014, the original anti-tumor new drug Chidamide was approved by the China Food and Drug Administration for marketing. Shenzhen Chipscreen Biosciences Co., Ltd. (Stock symbol: 688321.SH) has been listed on the SSE STAR Market on August 12, 2019.

About Chipscreen NewWay Biosciences

Chipscreen NewWay, affiliated with Chipscreen, is an innovative and R&D-driven biotech company dedicated to developing large molecules and other novel therapeutic modalities, including antibodies/ADC-centered large molecules, and nucleic acid drugs.

It develops innovative drugs that meet clinical needs and novel mechanisms of action in multiple therapeutic areas such as oncology and autoimmunity while providing patients with innovative mechanisms and globally leading-based new therapeutic approaches and options.

Chipscreen NewWay has built a large molecular R&D center of over 1,800 square meters in Chengdu Hi-Tech Zone and has established an experienced antibody and ADC R&D team from the discovery to the early process development, with a number of in-house and cooperation projects in continuous and rapid advancements.

To view this piece of content from, please give your consent at the top of this page.

Contact information

Biocytogen's Contacts
Antibody drug assets and platforms:

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Great Hill Partners Expands Presence Internationally with Opening of London Office20.3.2023 12:00:00 EET | Press release

Great Hill Partners, a private equity firm that invests in high-growth, disruptive companies, today announced that the firm has opened a London office to support its strong historical track record of investment activity in the UK and Europe. The London office will serve as Great Hill’s regional hub for the UK and Europe, providing the firm with a dedicated local presence, greater access to investment opportunities, and resources for portfolio companies. Longtime Great Hill Managing Director Drew Loucks will lead the new office and grow the London team. This press release features multimedia. View the full release here: (Photo: Business Wire) “Opening a London office is a natural next step for Great Hill," said Chris Gaffney, Managing Director at Great Hill. “We have more than a decade of experience investing in the UK and Europe, with a large and growing portfolio of international investments. The launch of a London office provi

Cirium Launches the First Airline Routes Tool Based on Satellite-Based Flight Tracking20.3.2023 11:00:00 EET | Press release

Cirium, the aviation analytics leader, has launched the aviation industry’s first Airline Routes tool to identify actual flights flown by aircraft type. This press release features multimedia. View the full release here: Cirium's Airline Routes tool analyzes an airline's routes using satellite-based flight tracking data to identify actual flights flown by aircraft type. (Photo: Business Wire) It uses applied analytics to derive routes flown by airlines based on satellite-based flight tracking and fuses this with advanced fleet data. The new premium Routes tool is part of Ascend Profiles, a visual descriptive analytics tool which enables businesses to quickly view aircraft intelligence by airline or lessor. Businesses such as aircraft lessors, banks or aircraft manufacturers are empowered to identify the aircraft flown by route for 1,700 airlines and factor development opportunities or risk into their decision making. By leveragi

2023 Harbin Ice & Snow Expo Was Successfully Held on March 17-1920.3.2023 10:55:00 EET | Press release

The 2023 Harbin Ice & Snow Expo, themed on "seeking development in the new paradigm and promoting the revitalization with ice and snow economy", was successfully held from 17 to 19 March in Harbin. It was hosted by Harbin Municipal People's Government, co-organized by CCPIT Harbin Committee and Beijing Zhenwei Exhibition Co., Ltd., and supported by Harbin Municipal Bureau of Culture, Radio, Television and Tourism. The Expo boasted a total exhibition area of 23,800 sqm, with 14 theme exhibition areas and nine international pavilions. Over 500 exhibitors in the ice-snow industry from 19 countries and regions, such as China, Canada, Iceland, France, Russia, Spain, etc., attended the event on online and offline platforms. Decathlon, POMA, Sany, XCMG, X-bionic, SUNAC SNOW PARK, HEILONG, Q.M.XUE LONG, Bombardier, Haxinlong Machinery, Fenlan Xuedong, Zhongcheng Technology, IWEIER STAR TECHNOLOGY, Ding Hongxin Sports Technology, TERROR, ADVANTURER and others showcased over 3,000 ice-snow exhib

Blackstone Announces Opening of New Office in Frankfurt, Germany20.3.2023 10:46:00 EET | Press release

Blackstone (NYSE: BX), the world’s largest alternative asset manager, today announced that it will open a new office in Frankfurt, Germany. The new flagship location will occupy 1,300 square meters in the OMNITURM in Frankfurt’s financial district and serve as a hub for Blackstone in Germany. The new office will host professionals across Blackstone’s private equity, real estate, and credit businesses, in addition to providing a hub for Blackstone’s private wealth solutions business, which serves investment professionals and individual investors across Europe. Juergen Pinker, Senior Managing Director, will lead on Private Equity, with Jurij Puth, Senior Managing Director, leading on Credit. Blackstone has been an active and significant investor in Germany for more than two decades, with currently more than 7,000 people employed by its portfolio companies in the country. To date, the firm has been involved in transactions worth more than €17 billion in Germany. The opening of the new off

Guardforce Security Adopts Hytera Push-to-talk to Improve Operational Efficiency20.3.2023 05:00:00 EET | Press release

Hytera Communications (SZSE: 002583), a leading global provider of professional communications technologies and solutions, has been providing Guardforce Security Thailand with its newest Push-to-Talk over Cellular (PoC) radios and Hytera HyTalk software suite to facilitate nationwide instant group communications and better team collaboration among Guardforce staff. This press release features multimedia. View the full release here: Guardforce security personnel on duty with Hytera PoC radios (Photo: Business Wire) Guardforce Thailand is a major security company that supplies technology-driven security solutions to a wide range of clients across Thailand, including banks, government organizations, retailers, shopping malls, hotels, airports, and enterprises. It currently employs approximately 5,000 security personnel nationwide across its three divisions. The security provider used to rely on analog two-way radios for communicati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom